Aerpio Pharmaceuticals Inc

NASDAQ:ARPO   3:59:43 PM EDT
1.96
+0.30 (+17.77%)
4:23:23 PM EDT: $1.94 -0.02 (-0.77%)
Regulatory, Earnings Announcements

Aerpio Announces Statistically Significant Topline Results From Razuprotafib Glaucoma Phase 2 Trial

Published: 12/11/2020 22:06 GMT
Aerpio Pharmaceuticals Inc (ARPO) - Aerpio Announces Statistically Significant Topline Results From Razuprotafib Glaucoma Phase 2 Trial.
Aerpio Pharmaceuticals Inc - Primary Endpoint Achieved With Twice-daily Dose Group at 28 Day Time Point Versus Latanoprost Control Group.
Aerpio Pharmaceuticals Inc - Patient Enrollment and Dosing Continues in Both Covid-19 Clinical Trials.
Aerpio - 2 Ongoing Clinical Trials of Razuprotafib in Covid-19 Patients Continue, Remain on Track to Provide Additional Updates in H1 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.06

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.06

More details on our Analysts Page.